ClinicalTrials.gg
CompletedNCT00913029SLUpdated May 20, 2015

Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)

A Phase 4 interventional study of iStent and latanoprost/timolol in Eye Diseases, Glaucoma, Open-Angle and Glaucoma, sponsored by Glaukos Corporation. Completed at 16 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-20.

Primary conditionGlaucoma, Open-AngleRegistry: Eye DiseasesReclassifiedWhy we changed it
Registry
Eye Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Eye Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Glaukos Corporation · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing latanoprost in Glaucoma, Open-Angle — none open to participants now, none under way, none of them phase 3. Latanoprost · Glaucoma, Open-Angle.

Enrollment
15th of 39
192 · median 117
Started
2009
with 3 others
Phase 4
15 of 40
none open now
Registered
21st of 40
by date

Among the 40 studies testing latanoprost in Glaucoma, Open-Angle, this one is the 15th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2009, is one of 15 in phase 4, and was the 21st registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

None of the 40 studies testing latanoprost in Glaucoma, Open-Angle is open now. The open studies under Glaucoma, Open-Angle, anywhere →

About latanoprost

Latanoprost: first FDA approval 1996 (XALATAN), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing latanoprost in Glaucoma, Open-Angle as a file.
02

Study summary

Prospective, unmasked, randomized evaluation of the iStent in patients with primary open-angle glaucoma. Patients will be randomized to one of two groups: 1) iStent, or 2) medication.

Read the detailed description

Two hundred patients will be enrolled in the study at up to 21 clinical sites; follow-up is through 1 year.

03

Conditions studied

  • Eye Diseases
  • Glaucoma, Open-Angle
  • Glaucoma

Browse trials for

Keywords

  • primary open angle glaucoma (POAG)
  • OAG
  • glaucoma
04

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

This study's enrollment of 192 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Eye Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary open-angle glaucoma
  • Male or female at least 18 years of age and able to provide written
  • Mean IOP (at baseline visit after washout of any medications) must be 22 mm Hg and no greater than 38 mm Hg
  • Likely to be available and willing to attend follow-up visits

Exclusion criteria

Exclusion Criteria:

  • Angle closure glaucoma
  • Secondary glaucomas
  • Prior glaucoma procedures
  • Elevated episcleral venous pressure from history of active thyroid orbitopathy, carotid-cavernous fistula, orbital tumors, or orbital congestive disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (actual)

Study arms

  • Active comparator
    Stent

    One hundred patients will be randomized to implantation of two G2 stents in at least one eye.

    Device: iStent

  • Active comparator
    Medication

    One hundred patients will be randomized to receive a fixed combination ocular hypotensive medication.

    Drug: latanoprost/timolol

Interventions

  • DeviceiStent

    iStent

    Also known as: stent, Trabecular micro bypass

  • Druglatanoprost/timolol

    Drug pages: Latanoprost · Timolol

    Combination latanoprost/timolol

07

What researchers measure

Primary outcomes

  1. Mean intraocular pressure (IOP)

    Time frame: 1 year

08

Study locations

16 sites
  • SV Malayan Ophthalmological Center
    Yerevan, Armenia
  • Allgemeines Krankenhaus Wien
    Wien, 1090, Austria
  • CHU de Lyon Hopital Edouard Herriot
    Lyon, 69437, France
  • CHNO des Quinze-Vingts
    Paris, 75012, France
  • Knapschaftskrankenhaus Bochum Langendreer
    Bochum, 44892, Germany
  • Helios Cliniic
    Erfurt, 99089, Germany
  • Universitatsklinkum Erlangen
    Erlangen, Germany
  • AHEPA Hospital
    Thessaloniki, 546 36, Greece
  • Universita'degli Studi di Parma
    Parma, 43100, Italy
  • Universita' di Torino/Dipartimento di Fisiopatologia Clinica-Clinica Oculistica
    Torino, 10128, Italy
  • Azienda Ospedaliera S. Maria della Misericordia
    Udine, 33100, Italy
  • Military Health Service Institute
    Warsaw, 00-909, Poland
  • Hospital Torrevieja Salud, UTE
    Alicante, 03186, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, Spain
  • Hinchingbrooke Hospital Moorfields
    Bedford, United Kingdom
09

References and documents

Publications

  • Fea AM, Belda JI, Rekas M, Junemann A, Chang L, Pablo L, Voskanyan L, Katz LJ. Prospective unmasked randomized evaluation of the iStent inject ((R)) versus two ocular hypotensive agents in patients with primary open-angle glaucoma. Clin Ophthalmol. 2014 May 7;8:875-82. doi: 10.2147/OPTH.S59932. eCollection 2014. PubMed 24855336 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2009
First posted
Jun 3, 2009
Start
May 2009
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Last update
May 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00913029
Responsible party
Sponsor
First posted
Jun 3, 2009
Start date
May 2009
Primary completion
Sep 2012
Completion
Sep 2012
Last update
May 20, 2015

Study contacts

Jeff Wells, PharmD, MBA
study director · Glaukos Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Latanoprost · Timolol

Start the discussion